A Study to Evaluate ASP0367 in Participants With Primary Mitochondrial Myopathy

PHASE2TerminatedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

May 24, 2021

Primary Completion Date

May 8, 2024

Study Completion Date

May 8, 2024

Conditions
Primary Mitochondrial Myopathy
Interventions
DRUG

Bocidelpar

Oral

DRUG

Placebo

Oral

Trial Locations (11)

10032

Columbia University Irving Medical Center, New York

19104

Children's Hospital of Philadelphia, Philadelphia

44195

Cleveland Clinic, Cleveland

44308

Akron Children's Hospital, Akron

77030

Baylor College of Medicine, Houston

University of Texas Health Science Center at Hosuton, Houston

80045

Children's Hospital Colorado, Aurora

92093

University of California, San Diego, La Jolla

94305

Stanford University Medical Center, Stanford

98105

Seattle Children's Hospital, Seattle

02114

Massachusetts General Hospital, Boston

Sponsors
All Listed Sponsors
lead

Astellas Pharma Inc

INDUSTRY